Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0102 USD | -7.27% | -37.04% | -83.78% |
May. 24 | Roche, LumiraDx Deal Probed by U.K. Competition Watchdog | DJ |
May. 20 | U.K. Competition Watchdog Weighs Potential Impact of Roche-LumiraDx | DJ |
Financials (USD)
Sales 2021 | 421.43 | Sales 2022 | 254.48 | Capitalization | 286M |
---|---|---|---|---|---|
Net income 2021 | -101M | Net income 2022 | -448M | EV / Sales 2021 | 5,817,897 x |
Net Debt 2021 | 200M | Net Debt 2022 | 347M | EV / Sales 2022 | 2,487,758 x |
P/E ratio 2021 |
-14.4
x | P/E ratio 2022 |
-0.57
x | Employees | 1,210 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99% |
Latest transcript on LumiraDx Limited
1 day | -7.27% | ||
1 week | -37.04% | ||
Current month | -49.00% | ||
1 month | -57.32% | ||
3 months | +13.33% | ||
6 months | -91.79% | ||
Current year | -83.78% |
Managers | Title | Age | Since |
---|---|---|---|
Ron Zwanziger
CEO | Chief Executive Officer | 70 | 13-12-31 |
Dave Scott
FOU | Founder | 67 | 13-12-31 |
Dorian LeBlanc
DFI | Director of Finance/CFO | 49 | 16-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dave Scott
FOU | Founder | 67 | 13-12-31 |
Ron Zwanziger
CEO | Chief Executive Officer | 70 | 13-12-31 |
Troyen Brennan
BRD | Director/Board Member | 69 | 16-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-12 | 0.0102 | -7.27% | 4 827 |
24-06-11 | 0.011 | 0.00% | 482,155 |
24-06-10 | 0.011 | -2.22% | 297,278 |
24-06-07 | 0.0112 | -18.48% | 1,320,079 |
24-06-06 | 0.0138 | -14.81% | 639,310 |
Delayed Quote OTC Markets, June 12, 2024 at 10:58 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-83.78% | 3.95M | |
+8.80% | 220B | |
+14.50% | 194B | |
+26.72% | 149B | |
+34.03% | 113B | |
+4.49% | 65.75B | |
+15.53% | 52.43B | |
+1.93% | 50.47B | |
-4.33% | 38.54B | |
-2.08% | 34.12B |
- Stock Market
- Equities
- LMDXF Stock